AI firm OpenEvidence secured $210 million in a Series B funding round to enhance its strategic content agreements and develop its medical knowledge repository. OpenEvidence has created an AI-driven health-related search engine and generative AI chatbot specifically for medical professionals, which summarizes and clarifies proof-based medical data.
Google Ventures led the Series B funding round jointly with Kleiner Perkins. Sequoia Capital, which spearheaded OpenEvidence’s $75 million Series A funding round in early 2025, was also among the backers, as were Thrive and Conviction.
OpenEvidence has secured over $300 million since its inception, and this recent financing elevates its worth to $3.5 billion, the firm stated. Established in 2022 by Daniel Nadler, Ph.D., the company claims that it is the most extensively used medical search engine amongst U.S. medical professionals, stating that over 40% of doctors in the country engage with its platform.
OpenEvidence is seeing significant growth. The firm claims that it is used in over 10,000 hospitals and medical institutions nationally, with an increase of over 65,000 new authorized U.S. clinician registrations on a monthly basis.
OpenEvidence Raises Over $200M, Showcases New AI Agents
The firm claims that its service has had a growth rate of 2,000% year-over-year. Last year in July, it facilitated nearly 360,000 medical consultations during a single month. One year later, the company currently manages that volume daily and facilitates nearly 9,000,000 clinical consultations by doctors each month, according to executives.
The startup provides its chatbot to physicians at no cost, and the product has expanded organically via referrals among doctors, Nadler said. He observed that it has purposely distinguished itself from other healthcare chatbots that use AI by being an early entrant and accumulating clinical consultations, in addition to its content collaborations with esteemed medical publications that reflect the highest levels of medical expertise.
Nadler saw the emergence of AI copilots as comparable to the commoditization of TV streaming services, where the emphasis is on content. Using OpenEvidence as an example, he noted that a doctor asking a clinical question on that platform would receive a highly specific answer – such as details about a study’s control group, efficiency breakdown across groups, or impacts on pregnant versus non-pregnant women. On the other hand, a general tool like ChatGPT might only return a broad, abstract-level response scraped from the public internet.
OpenEvidence utilizes reliable sources of outstanding scientific information to guide its responses, providing doctors, medical investigators, and healthcare professionals with expedited access to clinically applicable material, as stated by the firm. The platform swiftly reveals important medical information, integrates scientific research, and empowers physicians to make quicker, evidence-based choices.
In addition to the new capital, the company also introduced an AI agent specifically designed for clinicians to facilitate improved medical research. Named DeepConsult, the AI agent practically serves as a digital replica of a researcher with a Ph.D., as stated by Nadler.
Health technology startup OpenEvidence has announced a successful funding round of more than $200 million, marking one of the largest raises in the sector this year. The investment will support the company’s expansion and the further development of its cutting-edge AI-powered medical research platform.
With this new funding, OpenEvidence plans to scale its infrastructure, expand its team of experts, and accelerate product development aimed at transforming how clinicians and researchers access real-time medical insights. Investors noted that OpenEvidence stands out for its ability to combine advanced machine learning with trustworthy healthcare data, giving professionals reliable tools for decision-making.
The company also unveiled a suite of new AI agents designed to simplify clinical workflows, speed up evidence synthesis, and improve patient outcomes. These innovations position OpenEvidence at the forefront of the growing health AI market.
Industry analysts believe OpenEvidence could become a key player in bridging the gap between raw medical data and actionable clinical knowledge. By focusing on transparency, security, and scalability, OpenEvidence is setting new standards for how artificial intelligence can support modern healthcare.
